文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

清醒俯卧位对有COVID-19和急性呼吸衰竭患者气管插管的影响:一项随机临床试验

Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在COVID-19急性低氧性呼吸衰竭未插管成人中,清醒俯卧位较常规护理未显著降低30天气管插管率(34.1% vs 40.5%,HR 0.81,95%CI 0.59-1.12,P=0.20)。

这项在加拿大、科威特、沙特阿拉伯和美国21家医院开展的务实、非盲随机临床试验,纳入400例未插管、需氧疗(≥40%)或无创通气的COVID-19成人患者,随机分为清醒俯卧位组(n=205)和常规护理不俯卧位组(n=195)。随机后前4天,俯卧位组中位俯卧位时间为4.8 h/d(IQR 1.8-8.0 h/d),对照组为0 h/d(IQR 0-0 h/d)。主要终点30天内气管插管率在俯卧位组为34.1%(70/205),对照组为40.5%(79/195),HR 0.81(95%CI 0.59-1.12),P=0.20,绝对差-6.37%(95%CI -15.83%至3.10%)。60天死亡率无显著降低(HR 0.93,95%CI 0.62-1.40,P=0.54,绝对差-1.15%,95%CI -9.40%至7.10%),30天无创/有创机械通气天数及60天无ICU/住院天数均无显著影响。两组均无严重不良事件;俯卧位组21例(10%)发生不良事件,最常见为俯卧位相关肌肉骨骼疼痛或不适(13/205,6.34%)和血氧饱和度下降(2/205,0.98%),对照组无不良事件报告。作者结论认为效应量不精确,不能排除临床重要获益。

要点

  • 在COVID-19急性低氧性呼吸衰竭未插管成人中,清醒俯卧位较常规护理未显著降低30天气管插管率(34.1% vs 40.5%,HR 0.81,95%CI 0.59-1.12,P=0.20)。
  • 俯卧位组60天死亡率34.1%?原文未给出死亡率百分比,仅HR 0.93(95%CI 0.62-1.40,P=0.54),绝对差-1.15%(95%CI -9.40%至7.10%)。
  • 俯卧位组前4天中位俯卧位时间4.8 h/d(IQR 1.8-8.0 h/d),对照组0 h/d(IQR 0-0 h/d)。
  • 两组均无严重不良事件;俯卧位组21例(10%)发生不良事件,最常见为肌肉骨骼疼痛或不适(13/205,6.34%)和血氧饱和度下降(2/205,0.98%),对照组无不良事件报告。
  • 作者结论:主要结局效应量不精确,不能排除临床重要获益。

适用人群与场景

  • Canada、Kuwait、Saudi Arabia、US 21家医院成人COVID-19患者,未插管,需要氧疗(≥40%)或无创通气。

处置流程与药物剂量

  • 干预组:清醒俯卧位,前4天中位俯卧位时间4.8 h/d(IQR 1.8-8.0 h/d)。
  • 对照组:常规护理不俯卧位,前4天中位俯卧位时间0 h/d(IQR 0-0 h/d)。

研究设计与关键结果

  • 研究类型:务实、非盲随机临床试验;21家医院;纳入400例,随机分为清醒俯卧位组(n=205)和对照组(n=195);平均年龄57.6岁(SD 12.83),女性117例(29.3%);全部完成试验。
  • 主要终点:30天内气管插管率俯卧位组34.1%(70/205) vs 对照组40.5%(79/195),HR 0.81(95%CI 0.59-1.12),P=0.20;绝对差-6.37%(95%CI -15.83%至3.10%)。
  • 次要终点:60天死亡率HR 0.93(95%CI 0.62-1.40),P=0.54;绝对差-1.15%(95%CI -9.40%至7.10%);30天无创/有创机械通气天数及60天无ICU/住院天数均无显著影响。
  • 不良事件:两组均无严重不良事件;俯卧位组21例(10%)发生不良事件,最常见为肌肉骨骼疼痛或不适(13/205,6.34%)和血氧饱和度下降(2/205,0.98%);对照组无不良事件报告。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 局限:作者结论指出主要结局效应量不精确,不能排除临床重要获益。

对床旁实践的改变

  • 作者认为:在COVID-19急性低氧性呼吸衰竭患者中,清醒俯卧位较常规护理未显著降低30天气管插管率,但效应量不精确,不能排除临床重要获益。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT04350723

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The efficacy and safety of prone positioning is unclear in nonintubated patients with acute hypoxemia and COVID-19.

OBJECTIVE: To evaluate the efficacy and adverse events of prone positioning in nonintubated adult patients with acute hypoxemia and COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, unblinded randomized clinical trial conducted at 21 hospitals in Canada, Kuwait, Saudi Arabia, and the US. Eligible adult patients with COVID-19 were not intubated and required oxygen (≥40%) or noninvasive ventilation. A total of 400 patients were enrolled between May 19, 2020, and May 18, 2021, and final follow-up was completed in July 2021.

INTERVENTION: Patients were randomized to awake prone positioning (n = 205) or usual care without prone positioning (control; n = 195).

MAIN OUTCOMES AND MEASURES: The primary outcome was endotracheal intubation within 30 days of randomization. The secondary outcomes included mortality at 60 days, days free from invasive mechanical ventilation or noninvasive ventilation at 30 days, days free from the intensive care unit or hospital at 60 days, adverse events, and serious adverse events.

RESULTS: Among the 400 patients who were randomized (mean age, 57.6 years [SD, 12.83 years]; 117 [29.3%] were women), all (100%) completed the trial. In the first 4 days after randomization, the median duration of prone positioning was 4.8 h/d (IQR, 1.8 to 8.0 h/d) in the awake prone positioning group vs 0 h/d (IQR, 0 to 0 h/d) in the control group. By day 30, 70 of 205 patients (34.1%) in the prone positioning group were intubated vs 79 of 195 patients (40.5%) in the control group (hazard ratio, 0.81 [95% CI, 0.59 to 1.12], P = .20; absolute difference, -6.37% [95% CI, -15.83% to 3.10%]). Prone positioning did not significantly reduce mortality at 60 days (hazard ratio, 0.93 [95% CI, 0.62 to 1.40], P = .54; absolute difference, -1.15% [95% CI, -9.40% to 7.10%]) and had no significant effect on days free from invasive mechanical ventilation or noninvasive ventilation at 30 days or on days free from the intensive care unit or hospital at 60 days. There were no serious adverse events in either group. In the awake prone positioning group, 21 patients (10%) experienced adverse events and the most frequently reported were musculoskeletal pain or discomfort from prone positioning (13 of 205 patients [6.34%]) and desaturation (2 of 205 patients [0.98%]). There were no reported adverse events in the control group.

CONCLUSIONS AND RELEVANCE: In patients with acute hypoxemic respiratory failure from COVID-19, prone positioning, compared with usual care without prone positioning, did not significantly reduce endotracheal intubation at 30 days. However, the effect size for the primary study outcome was imprecise and does not exclude a clinically important benefit.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04350723.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Alhazzani W, Parhar KKS, Weatherald J, et al. Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial. JAMA. 2022. PMID: 35569448. doi:10.1001/jama.2022.7993

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。